Literature DB >> 22869282

The emerging role of amiodarone and dronedarone in Chagas disease.

Gustavo Benaim1, Alberto E Paniz Mondolfi.   

Abstract

Chagas disease has emerged as an important health problem in the Americas and, with globalization, in other parts of the world. Drug therapy for this parasitic infection has remained largely ineffective, especially in chronic stages of the disease. However, developments in experimental therapy might signal an important advance for the management of patients with Chagas disease. Herein, we review studies on the potential use of the benzofuran derivatives amiodarone and dronedarone in patients with Chagas disease. These agents have a dual role, not only as primary antiarrhythmic drugs, but also as antiparasitic agents. We believe that this 'kill two birds with one stone' approach represents a new tactic for the treatment of Chagas disease using currently approved drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869282     DOI: 10.1038/nrcardio.2012.108

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  34 in total

Review 1.  Specific chemotherapy of Chagas disease: controversies and advances.

Authors:  Julio A Urbina; Roberto Docampo
Journal:  Trends Parasitol       Date:  2003-11

2.  Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.

Authors:  Daniel Adesse; Eduardo Meirelles Azzam; Maria de Nazareth L Meirelles; Julio A Urbina; Luciana R Garzoni
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi.

Authors:  Phercyles Veiga-Santos; Emile S Barrias; Júlio F C Santos; Thiago Luiz de Barros Moreira; Tecia Maria Ulisses de Carvalho; Julio A Urbina; Wanderley de Souza
Journal:  Int J Antimicrob Agents       Date:  2012-05-14       Impact factor: 5.283

4.  Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrhythmias.

Authors:  Augusto Cardinalli-Neto; Osvaldo T Greco; Reinaldo B Bestetti
Journal:  Pacing Clin Electrophysiol       Date:  2006-05       Impact factor: 1.976

5.  Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate.

Authors:  Eric N Prystowsky
Journal:  Nat Rev Cardiol       Date:  2010-01       Impact factor: 32.419

6.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

Authors:  Jose Antonio Marin-Neto; Anis Rassi; Carlos A Morillo; Alvaro Avezum; Stuart J Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf
Journal:  Am Heart J       Date:  2008-07       Impact factor: 4.749

7.  "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.

Authors:  R L Tarleton; L Zhang; M O Downs
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 8.  Chemotherapy of Chagas' disease: the how and the why.

Authors:  J A Urbina
Journal:  J Mol Med (Berl)       Date:  1999-03       Impact factor: 4.599

9.  Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms.

Authors:  A H Haedo; P A Chiale; J D Bandieri; J O Lázzari; M V Elizari; M B Rosenbaum
Journal:  J Am Coll Cardiol       Date:  1986-05       Impact factor: 24.094

10.  Chagas disease: "the new HIV/AIDS of the Americas".

Authors:  Peter J Hotez; Eric Dumonteil; Laila Woc-Colburn; Jose A Serpa; Sarah Bezek; Morven S Edwards; Camden J Hallmark; Laura W Musselwhite; Benjamin J Flink; Maria Elena Bottazzi
Journal:  PLoS Negl Trop Dis       Date:  2012-05-29
View more
  20 in total

Review 1.  Resistance-resistant antibiotics.

Authors:  Eric Oldfield; Xinxin Feng
Journal:  Trends Pharmacol Sci       Date:  2014-11-05       Impact factor: 14.819

2.  SQ109, a new drug lead for Chagas disease.

Authors:  Phercyles Veiga-Santos; Kai Li; Lilianne Lameira; Tecia Maria Ulisses de Carvalho; Guozhong Huang; Melina Galizzi; Na Shang; Qian Li; Dolores Gonzalez-Pacanowska; Vanessa Hernandez-Rodriguez; Gustavo Benaim; Rey-Ting Guo; Julio A Urbina; Roberto Docampo; Wanderley de Souza; Eric Oldfield
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Pleiotropic actions of amiodarone: still puzzling after half a century.

Authors:  Jordi Heijman; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-09       Impact factor: 3.000

Review 4.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.

Authors:  Andre A L Carmo; Manoel O C Rocha; Jose L P Silva; Barbara M Ianni; Fabio Fernandes; Ester C Sabino; Antonio L P Ribeiro
Journal:  Int J Cardiol       Date:  2015-04-11       Impact factor: 4.164

6.  Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca2+ Channel.

Authors:  Andrea K Pinto-Martinez; Jessica Rodriguez-Durán; Xenon Serrano-Martin; Vanessa Hernandez-Rodriguez; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109.

Authors:  Verónica García-García; Eric Oldfield; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Dronedarone, an amiodarone analog with improved anti-Leishmania mexicana efficacy.

Authors:  Gustavo Benaim; Paola Casanova; Vanessa Hernandez-Rodriguez; Sheira Mujica-Gonzalez; Nereida Parra-Gimenez; Lourdes Plaza-Rojas; Juan Luis Concepcion; Yi-Liang Liu; Eric Oldfield; Alberto Paniz-Mondolfi; Alirica I Suarez
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

9.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

10.  SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca2+ homeostasis, collapsing the mitochondrial electrochemical potential (ΔΨm) and affecting acidocalcisomes.

Authors:  Zain Gil; Nathalia Martinez-Sotillo; Andrea Pinto-Martinez; Fabiola Mejias; Juan Carlos Martinez; Ivan Galindo; Eric Oldfield; Gustavo Benaim
Journal:  Parasitol Res       Date:  2020-01-02       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.